Effects of CYP2D6 and CYP3A5 polymorphisms on tamoxifen and its metabolites in Thai breast cancer patients
Wanaporn Charoenchokthavee,1 Nutthada Areepium,2 Duangchit Panomvana,2 Virote Sriuranpong2 1Department of Pharmacy Practice, Faculty of Pharmaceutical Science, Chulalongkorn University, 2Medical Oncology Unit, Department of Medicine, Faculty of Medicine, Chulalongkorn University, Pathumwan, Bangkok,...
Guardado en:
Autores principales: | Charoenchokthavee W, Areepium N, Panomvana D, Sriuranpong V |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Dove Medical Press
2017
|
Materias: | |
Acceso en línea: | https://doaj.org/article/d0364aaba98542d18bb14c266e0b0865 |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Prevalence of CYP2D6*2, CYP2D6*4, CYP2D6*10, and CYP3A5*3 in Thai breast cancer patients undergoing tamoxifen treatment
por: Charoenchokthavee W, et al.
Publicado: (2016) -
CYP2D6 polymorphisms may predict occurrence of adverse effects to tamoxifen: a preliminary retrospective study
por: Wickramage I, et al.
Publicado: (2017) -
Association between telomere length and CYP19 TTTA repetition polymorphism in healthy and breast cancer-diagnosed women
por: Murillo-Ortiz B, et al.
Publicado: (2017) -
Effects of CYP2D6 and UGT2B7 polymorphisms on pharmacokinetics of tamoxifen in Thai breast cancer patients
por: Areepium N, et al.
Publicado: (2013) -
Elección del mejor antidepresivo en pacientes con cáncer de mama en tratamiento con tamoxifeno: revisión de la evidencia básica y clínica
por: Irarrázaval O,María Elisa, et al.
Publicado: (2016)